RCKT ROCKET PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1281895 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY93.3%
TTM EPS YoY93.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-5.0%
ROA-4.1%
ROIC (approx.)-60.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.09x
Current ratio7.26x
Interest coverage-100.61x
Cash quality & payout
Operating cash flow / net income9.84x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $31.17M | $29.50M | $31.45M | $29.35M | $34.07M | $42.66M | $35.94M | $37.36M |
| SG&A expense | $19.79M | $17.43M | $17.06M | $14.68M | $18.35M | $25.02M | $28.45M | $25.34M |
| Operating income | -$50.97M | -$46.92M | -$48.51M | -$43.96M | -$52.25M | -$71.15M | -$64.39M | -$62.69M |
| Interest expense | $473,000 | $473,000 | $473,000 | $473,000 | $473,000 | $473,000 | $472,000 | $473,000 |
| Pretax income | -$49.18M | $131.84M | — | -$42.54M | -$50.33M | -$68.92M | — | — |
| Income tax | $54,000 | $8.62M | — | $0 | $0 | $0 | — | — |
| Net income | -$49.23M | $123.21M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | -$61.33M | -$60.33M |
| EBITDA | -$49.47M | -$45.32M | -$46.91M | -$42.26M | -$49.55M | -$69.15M | -$61.89M | -$60.89M |
| EPS (basic) | -0.43 | 1.09 | -0.42 | — | -0.45 | -0.62 | -0.56 | — |
| EPS (diluted) | -0.43 | 1.08 | -0.42 | — | -0.45 | -0.62 | -0.56 | — |
| Weighted avg. shares (diluted) | 113.65M | 114.51M | 112.13M | — | 111.57M | 111.02M | 110.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $95.47M | $224.51M | $49.61M | $77.56M | $77.31M | $34.18M | $51.17M | $165.00M |
| Short-term investments | $174.04M | $59.24M | $94.77M | $111.37M | $146.81M | $238.68M | $268.35M | $208.70M |
| Inventory | $393,000 | — | — | $0 | — | — | — | — |
| Current assets | $278.05M | $289.55M | $149.83M | $192.73M | $227.68M | $277.15M | $324.49M | $378.18M |
| PP&E, net | $23.76M | $25.10M | $26.66M | $28.17M | $29.77M | $32.52M | $34.56M | $36.79M |
| Goodwill | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M |
| Intangibles | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M |
| Total assets | $419.50M | $423.10M | $285.41M | $330.45M | $368.03M | $420.98M | $471.07M | $527.70M |
| Current liabilities | $38.32M | $31.32M | $24.47M | $30.21M | $31.17M | $43.40M | $35.31M | $40.68M |
| Short-term debt | $0 | — | — | — | — | — | — | — |
| Long-term debt | $30.43M | — | — | $0 | — | — | — | — |
| Total debt | $30.43M | — | — | $0 | — | — | — | — |
| Total liabilities | $92.78M | $54.27M | $47.37M | $53.23M | $54.36M | $66.77M | $58.93M | $64.47M |
| Shareholders' equity | $326.72M | $368.83M | $238.04M | $277.22M | $313.67M | $354.21M | $412.14M | $463.23M |
| Net debt | -$65.04M | — | — | -$77.56M | — | — | — | — |
| Shares outstanding | 111.39M | 109.54M | 109.12M | 108.32M | 108.21M | 107.88M | 106.75M | 106.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$39.05M | -$39.61M | -$45.39M | -$34.84M | -$50.42M | -$48.96M | -$55.79M | -$46.94M |
| Capital expenditure | $151,000 | $8,000 | $93,000 | $80,000 | -$54,000 | $50,000 | $364,000 | $309,000 |
| Free cash flow | -$39.20M | -$39.62M | -$45.49M | -$34.92M | -$50.37M | -$49.01M | -$56.15M | -$47.25M |
| Investing cash flow | -$124.02M | $214.36M | $17.45M | $36.42M | $93.62M | $31.76M | -$58.03M | -$37.87M |
| Financing cash flow | $34.03M | $150,000 | -$1,000 | $0 | -$67,000 | $215,000 | $0 | $182.85M |
| Depreciation & amortization | $1.50M | $1.60M | $1.60M | $1.70M | $2.70M | $2.00M | $2.50M | $1.80M |
| Stock-based compensation | $7.35M | $7.42M | $8.49M | $6.11M | $9.76M | $10.86M | $10.33M | $11.09M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.